Literature DB >> 213096

Cell membrane enzymes. II. Alkaline phosphatase and alkaline phosphodiesterase I in normal and leukaemic lymphocytes.

M T Kramers, D Catovsky, R Foa.   

Abstract

The distribution of two cell membrane enzymes, alkaline phosphatase and alkaline phosphodiesterase I has been studied in normal and leukaemic lymphocytes. No reduction in the level of activity of either enzyme was found in the chronic or acute B- and T-cell leukaemias. Alkaline phosphatase activity was elevated in the lymphocytes from T-CLL, cord blood and tonsils and the blast cells from Null-ALL. Alkaline phosphodiesterase was elevated in lymphocytes from cord blood and tonsils and the blast cells from Null-ALL. As findings in Null-ALL were based on only two cases, they need confirmation in a larger series. The significance of these results is discussed in relation to current theories of maturation and differentiation in the lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 213096     DOI: 10.1111/j.1365-2141.1978.tb03644.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Studies on lymphocyte cell surface in ataxia-telangiectasia.

Authors:  N K Ozer; G Ciliv; A I Berkel; O Sanal; O Yeğin; F Ersoy
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Alkaline phosphatase in human lymphocyte subpopulations.

Authors:  R Foa; M T Kramers; D Catovsky
Journal:  Experientia       Date:  1979-02-15

3.  An in vitro screening system for the nephrotoxicity of various platinum coordination complexes. A cytochemical study.

Authors:  M A Batzer; S K Aggarwal
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.

Authors:  D V Devine; W L Gluck; W F Rosse; J B Weinberg
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.